This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2013 report finds that the US government was again the biggest contributor and calls for other countries and sectors to step up to end a seven-year trend of flat funding. It also profiles growing interest in research on a therapeutic vaccines.
From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape
Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research & Development
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2012 report finds increased investment by private foundations was unable to make up for the effects of the economic downturn. It also highlights the contributions to prevention research of trial participants.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
2013 AVAC Report: Research and Reality
Research & Reality calls on funders and researchers to capitalize on lessons learned from a range of recent HIV prevention trials via better problem solving, more critical thinking and coordinated action. This year’s AVAC Report identifies progress and gaps in large-scale human trials, rollout of proven options and ongoing research for new advances that women and men will want to use.
2012 AVAC Report: Achieving the End—One Year and Counting
AVAC Report 2012, Achieving the End—One Year and Counting, sets a clock on the global drive to end the AIDS epidemic. The past twelve months have seen remarkable global consensus that it is possible to begin to end the epidemic. The same time period has seen concepts like “combination prevention” and “treatment as prevention” capture the world’s attention. But without specific interim goals—and far more precision about what combination prevention and other key concepts mean—the lofty goal of ending the epidemic will not be achieved.
2011 AVAC Report: The End?
The AVAC Report 2011, The End?, lays out a three-part, science-based agenda for ending the AIDS epidemic in our lifetimes. It synthesizes the actions need across the spectrum of existing, emerging and long-term biomedical HIV prevention tools that could change the AIDS response forever. This year’s Report also introduces the AVAC “Playbook” which is a new strategic document identifying global and organizational priorities for the year 2012.
2010 AVAC Report: Turning the Page
The AVAC 2010 Report, Turning the Page, highlights that the biomedical prevention field is entering the next chapter of its development. The past year brought the first evidence, from the Thai Prime-Boost trial, that an AIDS vaccine could prevent HIV in humans, as well as significant preclinical findings around potent, HIV-specific neutralizing antibodies.
At the same time, two microbicide trials testing the candidate PRO 2000 yielded seemingly different, but ultimately disappointing results, and the field now prepares for the release of results from CAPRISA 004, the first ARV-based microbicide effectiveness trial.
2009 AVAC Report: Piecing Together the HIV Prevention Puzzle
The 2009 AVAC Report, Piecing Together the HIV Prevention Puzzle, took inspiration from a quotation in the 2006-2008 review of the Bill & Melinda Gates Foundation-funded Collaboration for AIDS Vaccine Discovery, which states that the ultimate goal “is to develop a vaccine that prevents HIV infection or disease, anything less than that can be characterized as progress, but not success.”
The first section of the Report, “Puzzling Out Progress,” reports on the AIDS vaccine field, where there’s an energized focus on discovery, innovation, and basic science. The second section, “Puzzling Out Success,” turns to the implications of PrEP and other strategies in efficacy trials today. Throughout, it is argued that success will depend on combination approaches: on research plus implementation; on vaccines plus PrEP, should either show benefit; and on communities plus researchers working towards common goals.
2008 AVAC Report: The Search Must Continue
The 2008 AVAC Report, The Search Must Continue, provides a comprehensive review of recent developments in AIDS vaccine research. It explores the issues that have been raised in the wake of the failure of Merck’s vaccine candidate and provides context for the events and major changes of the last year in HIV prevention research.
2007 AVAC Report: Resetting the Clock
The three sections of this year’s report outline some specific deadlines and challenges in AIDS vaccine scientific strategy, clinical trials, and the broader realm of HIV prevention. These arenas mesh like watch gears, and must function just as smoothly if the field is to proceed.